loading page

Pros and cons: Should AIT be considered in all patients with allergic asthma?
  • Roy Gerth van Wijk,
  • Ronald Dahl
Roy Gerth van Wijk
Erasmus MC Afdeling Inwendige Geneeskunde
Author Profile
Ronald Dahl
Aarhus Universitet Tandlageskolen
Author Profile

Abstract

Allergen immunotherapy (AIT) has gained a permanent place in the therapeutic arsenal for the patient with allergy. Particularly, substantial evidence has been established for the efficacy of AIT in allergic rhinitis. A hallmark of AIT is it disease modifying effect resulting in persistent benefit after the treatment has been terminated. Both the subcutaneous and sublingual mode of administration appear to be safe. It is, however, a matter of debate whether AIT can be implemented for patients with asthma. EAACI and GINA guidelines recommend sublingual AIT in house dust mite driven asthma. The question however remains whether the different available forms of AIT should be used for allergic asthma in general.

Peer review status:ACCEPTED

27 Jul 2021Submitted to Allergy
27 Jul 2021Submission Checks Completed
27 Jul 2021Assigned to Editor
29 Jul 2021Reviewer(s) Assigned
08 Aug 2021Review(s) Completed, Editorial Evaluation Pending
12 Aug 2021Editorial Decision: Revise Minor
17 Aug 20211st Revision Received
17 Aug 2021Submission Checks Completed
17 Aug 2021Assigned to Editor
19 Aug 2021Reviewer(s) Assigned
19 Aug 2021Review(s) Completed, Editorial Evaluation Pending
23 Aug 20212nd Revision Received
24 Aug 2021Submission Checks Completed
24 Aug 2021Assigned to Editor
27 Aug 2021Review(s) Completed, Editorial Evaluation Pending
29 Aug 2021Editorial Decision: Accept